Edition:
United Kingdom

Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

7.64EUR
4:35pm BST
Change (% chg)

€0.16 (+2.14%)
Prev Close
€7.48
Open
€7.56
Day's High
€7.83
Day's Low
€7.50
Volume
139,889
Avg. Vol
126,093
52-wk High
€9.18
52-wk Low
€4.92

Latest Key Developments (Source: Significant Developments)

Poxel Updates On PXL065 Phase 1A Single Ascending Dose Trial
Monday, 8 Apr 2019 

April 8 (Reuters) - POXEL SA ::POXEL ANNOUNCES FAVORABLE RESULTS FOR PXL065 PHASE 1A SINGLE ASCENDING DOSE TRIAL.PXL065 OBSERVED TO HAVE A FAVORABLE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE IN PHASE 1A TRIAL.BASED ON FAVORABLE RESULTS IN PHASE 1A STUDY, COMPANY IS PREPARING TO INITIATE A PHASE 1B MAD TRIAL.DURING THE REMAINDER OF 2019, PREPARATION FOR THE PIVOTAL PHASE 2 PROGRAM OF PXL065 IN BIOPSY-PROVEN NASH PATIENTS WILL ALSO INCLUDE A PRE-INVESTIGATIONAL NEW DRUG MEETING WITH THE U.S. FDA TO DISCUSS THE NASH DEVELOPMENT STRATEGY.  Full Article

Poxel Q4 Revenue Grows To 19.6 Million Euros
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - POXEL SA ::POXEL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL UPDATE.POXEL REPORTED REVENUES OF EUR 19.6 MILLION FOR QUARTER ENDED DECEMBER 31, 2018.AS OF DECEMBER 31, 2018, CASH AND CASH EQUIVALENTS WERE EUR 66.7 MILLION.PXL770 FOR TREATMENT OF NASH IS EXPECTED TO ENTER A PHASE 2A PROGRAM DURING Q1 OF 2019.FOR PXL065, WE PLAN TO INITIATE PHASE 2 PROGRAM FOR TREATMENT OF NASH DURING SECOND HALF OF 2019 FOLLOWING COMPLETION OF PHASE 1 PROGRAM.  Full Article

Poxel H1 Operating Loss Turns To Profit Of 6.4 Million Euros
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - POXEL SA ::H1 REVENUES EUR 37.5 MILLION VERSUS NO REVENUE YEAR AGO.H1 OPERATING PROFIT EUR 6.4 MILLION VERSUS LOSS OF EUR 9.5 MILLION YEAR AGO.H1 NET PROFIT EUR 7.3 MILLION VERSUS LOSS OF EUR 9.7 MILLION YEAR AGO.  Full Article

Poxel FY Operating Loss Narrows To ‍​21.9 Million Euros
Thursday, 22 Mar 2018 

March 22 (Reuters) - POXEL SA ::FY OPERATING LOSS OF EUR ‍​21.9 MILLION VERSUS LOSS OF EUR 24.3 MILLION YEAR AGO.FY NET LOSS OF EUR 22.3‍​ MILLION VERSUS LOSS OF EUR 24.5 MILLION YEAR AGO.FY REVENUE EUR ‍5.3 MILLION VERSUS EUR 70,000 YEAR AGO.COMPLETED PHASE 2B FOR IMEGLIMIN.INITIATED PHASE 3 TIMES PROGRAM IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES‍​.  Full Article

Poxel Presents Preclinical Proof-Of-Concept Data For Pxl770
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - POXEL SA ::POXEL PRESENTS PRECLINICAL PROOF-OF-CONCEPT DATA FOR PXL770 IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) AT GLOBAL NASH CONGRESS 2018.PXL770 IS OBSERVED TO SIGNIFICANTLY REDUCE LIVER STEATOSIS AND NAS SCORE FOLLOWING 8 WEEKS OF TREATMENT VERSUS CONTROL.PXL770 IS OBSERVED TO SIGNIFICANTLY REDUCE EXPRESSION OF A PANEL OF KEY GENES ASSOCIATED WITH FIBROSIS.WE ARE PLANNING TO INITIATE A PHASE 2A PROOF-OF-CONCEPT STUDY IN PATIENTS WITH NAFLD -CEO.STUDY IS EXPECTED TO BEGIN DURING SECOND HALF OF 2018.WE ARE ALSO EXPLORING OTHER METABOLIC DISEASES FOR PROOF-OF-CONCEPT STUDIES FOR PXL770 -CEO.  Full Article

Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Monday, 30 Oct 2017 

Oct 30 (Reuters) - POXEL SA ::SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES.‍POXEL AND SUMITOMO DAINIPPON PHARMA TO JOINTLY DEVELOP IMEGLIMIN FOR TREATMENT OF TYPE 2 DIABETES IN JAPAN,​.‍SUMITOMO DAINIPPON PHARMA ASSUMES PHASE 3 AND COMMERCIALIZATION COSTS​.‍POXEL RECEIVES AN UPFRONT PAYMENT OF ¥4.75 BILLION (APPROXIMATELY EUR 36 MILLION, $42 MILLION)​.‍SUMITOMO DAINIPPON PHARMA SOLELY RESPONSIBLE FOR IMEGLIMIN IN CHINA, SOUTH KOREA, TAIWAN AND 9 OTHER SOUTHEAST ASIAN COUNTRIES​.‍PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN ON TRACK TO BE INITIATED IN Q4 OF CY 2017​.‍RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO ¥29.25 BILLION​.  Full Article

Poxel announces cash and cash equivalents at 30.0 million euros as of Sept. 30, 2017​
Monday, 16 Oct 2017 

Oct 16 (Reuters) - POXEL SA ::‍AS OF SEPTEMBER 30, 2017, CASH AND CASH EQUIVALENTS WERE EUR 30.0 MILLION​.‍POXEL DID NOT GENERATE SIGNIFICANT REVENUES IN Q3 OF 2017​.‍LOOKING FORWARD TO INITIATING PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN DURING Q4 OF THIS YEAR​.  Full Article

Poxel H1 net loss narrows to 9.7 million euros
Thursday, 21 Sep 2017 

Sept 21 (Reuters) - POXEL SA ::H1 NET LOSS EUR 9.7‍​ MILLION VERSUS LOSS OF EUR 12.4 MILLION YEAR AGO.H1 REVENUE NO REVENUE VERSUS NO TURNOVER YEAR AGO.H1 OPERATING LOSS EUR ‍​9.5 MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.AS OF JUNE 30, 2017, CASH AND CASH EQUIVALENTS WERE EUR €34.9 MILLION‍​.PLANS TO MOVE FORWARD WITH ITS IMEGLIMIN PHASE 3 PROGRAM DURING Q4 2017‍​.  Full Article

Poxel says ‍imeglimin Phase 2b trial achieved statistically significant results
Thursday, 14 Sep 2017 

Sept 14 (Reuters) - POXEL SA :‍IMEGLIMIN PHASE 2B TRIAL IN 299 JAPANESE PATIENTS ACHIEVED STATISTICALLY SIGNIFICANT RESULTS FOR ITS PRIMARY AND SECONDARY ENDPOINTS​.‍POXEL RECENTLY COMPLETED END OF PHASE 2 MEETING FOR IMEGLIMIN WITH JAPANESE REGULATORS AND PLANS TO INITIATE PHASE 3 PROGRAM IN Q4 OF 2017​.‍OVERALL, STUDY SHOWED THAT IMEGLIMIN WAS SAFE AND WELL TOLERATED​.  Full Article

Poxel presents new preclinical Imeglimin data
Monday, 28 Aug 2017 

Aug 28 (Reuters) - POXEL SA ::PRESENTS NEW PRECLINICAL IMEGLIMIN DATA DEMONSTRATING IMPROVEMENT OF BOTH PERIPHERAL AND CORONARY VASCULAR FUNCTION AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS.IMEGLIMIN HAS SUCCESSFULLY COMPLETED PHASE 1 AND PHASE 2 DEVELOPMENT IN OVER 1,200 SUBJECTS IN U.S., EU AND JAPAN.  Full Article